Contact us
Sitemap
Search
About
Products/Pipeline
Patients/Physicians
Investors/Media
Funding/Support
Careers
Contact us
Search
BioMarin
home
About us
A Message from the Chairman and CEO
Leadership Team
Jean-Jacques Bienaime
Robert A Baffi
Dr. Henry J. Fuchs
Daniel Spiegelman
Jeff Ajer
G. Eric Davis
Philip Lo Scalzo
Amy Wireman
Dr. Brinda Balakrishnan
Board of Directors
History
BioMarin 20 Year History
Global Compliance & Ethics Program
Corporate and Social Responsibility
Products/Pipeline
Overview
PALYNZIQ
™
Brineura
™
Vimizim
®
Kuvan
®
Naglazyme
®
Aldurazyme
®
Firdapse
®
Pipeline
Vosoritide (BMN 111) for Achondroplasia
Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A
Tralesinidase alfa (BMN 250) for MPS IIIB (Sanfilippo Syndrome B)
Clinical Trials
Achondroplasia
PKU
MPS IVA
MPS VI
CLN2 Disease
Hemophilia A
MPS IIIB (Sanfilippo B Syndrome)
Compassionate Use Policy
Patients/Physicians
Overview
Diseases
Lysosomal Storage Disorders
CLN2 Disease
MPS I
Morquio A (MPS IVA)
MPS VI
PKU
LEMS
Patient Stories
AnnaBelle
Julie
Gina
Lauren
Liam
Kendra
Tyler
Resource Library
Patient Organizations
Professional Organizations
Publications
Glossary
BioMarin RareConnections
™
Global Medical Information
Medical Information Request Form
Contact Information
Investors/Media
Press Releases
Events and Presentations
Corporate Governance
Management
Board of Directors
Committee Composition
Contact the Board
Financial Information
SEC Filings
Annual Reports
Quarterly Results
Key Ratios
Financial Statements
Analyst Coverage
Stock Information
Historic Stock Lookup
Investor FAQ
Contact Us
Email Alerts
Funding & Support
Guidelines for Requesting Grants and Charitable Contributions
Process for Requesting Grants
Applying for a Grant or Charitable Contribution
My Grants
FAQs
Contact Us
Global Independent Research Guidelines
Process
Apply
My Grants
FAQs
Contact Us
Rare Scholars
BioMarin in the Hemophilia Community
Careers
Innovative therapeutics
RSS Feed
sidebar_pipeline_pegpal
PEG-PAL is now in Phase 2 clinical development to treat patients who do not adequately respond to Kuvan.
BLANK
Top
